Dexfadrostat

Dexfadrostat ((R) -Fadrozole) is a potent nonsteroidal inhibitor[1]. Dexfadrostat also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.[1][2].

Product Specifications

CAS Number

[102676-87-9]

Product Name Alternative

(R) -Fadrozole; (R) -CGS 16949A (free base) ; FAD286

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/dexfadrostat.html

Concentration

10mM

Purity

98.75

Solubility

DMSO : 110 mg/mL (ultrasonic)

Smiles

N#CC1=CC=C([C@H]2CCCC3=CN=CN23)C=C1

Molecular Formula

C14H13N3

Molecular Weight

223.27

Precautions

H315, H319, H320

References & Citations

[1]Furet P, et al. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem. 1993;36 (10) :1393-1400.|[2]Minnaard-Huiban M, et al. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. Endocrinology. 2008;149 (1) :28-31.